Improving pancreatic cancer treatment for African Americans
Pilot Project 5
This study is looking at a new way to treat pancreatic cancer, especially for Black/African American patients, by testing a modified chemotherapy drug that might work better than the usual treatments, using special lab models made from patient cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-10932250 on NIH RePORTER |
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a highly aggressive cancer with low survival rates, particularly among Black/African American individuals. The study aims to enhance the effectiveness of a modified chemotherapy drug, 4-(N)-stearoylGem (4NSG), which is designed to improve drug delivery and reduce resistance in cancer cells. By using patient-derived organoid models, the research will evaluate how well this new treatment works compared to traditional therapies. The goal is to find a more effective treatment option that could lead to better outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include Black/African American individuals diagnosed with pancreatic ductal adenocarcinoma.
Not a fit: Patients who do not have pancreatic cancer or those outside the African American demographic may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and survival rates for patients with pancreatic cancer, particularly within the African American community.
How similar studies have performed: Previous research has shown promise in enhancing chemotherapy efficacy through modified drug delivery systems, suggesting potential success for this novel approach.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Han, Bo — University of Southern California
- Study coordinator: Han, Bo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.